Antifungal Efficacy during Candida krusei Infection in Non-Conventional Models Correlates with the Yeast In Vitro Susceptibility Profile
Figure 6
Efficacy of voriconazole, amphotericin B or caspofungin during C. krusei and C. albicans infection in G. mellonella.
A and B) Voriconazole treatment efficacy (7 and 10 mg/kg) in G. mellonella infected with C. albicans SC5314 (A) or C. krusei ATCC 6258 (B). C and D) Amphotericin B treatment efficacy (1, 2, 4 mg/kg) in G. mellonella infected with C. albicans SC5314 (C) or C. krusei ATCC 6258 (D). E and F) Caspofungin treatment efficacy (1, 2, 4 mg/kg) in G. mellonella infected with C. albicans SC5314 (E) or Candida krusei ATCC 6258 (F). In all the cases, the larvae were infected with 5×105 C. albicans cells/larva and 5×106 C. krusei cells/larva.